Quantcast

Latest Sinovac Biotech Stories

2014-04-16 08:34:34

BEIJING, April 16, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2013 on April 16, 2014. The Annual Report on Form 20-F is now available on the Company's website under SEC...

2014-03-25 08:23:39

DUBLIN, Mar. 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/n86mjg/china_human ) has announced the addition of the "Concise Analysis of the International Human Vaccine Industry" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5...

2014-03-20 16:26:59

DUBLIN, March 20, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/n8dfqv/china_influenza) has announced the addition of the "China Influenza Vaccine Industry Report 2014" [http://www.researchandmarkets.com/research/n8dfqv/china_influenza ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The China Influenza Vaccine Industry Report 2014 is a professional and in-depth study on the...

2014-03-19 20:21:13

- Conference call scheduled for Thursday, March 20, 2014 at 8:00 AM EDT - BEIJING, March 19, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December 31, 2013. Unaudited Fourth Quarter 2013 Financial Highlights (period-over-period comparisons to fourth quarter 2012) -- Quarterly sales increased by 17.1% to $22.9 million...

2014-03-12 08:29:43

BEIJING, March 12, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014 EDT. The Company will host a conference call prior to the market opening on Thursday, March 20, 2014, at 8:00 a.m. EDT (Thursday, March 20, 2014 at 8:00 p.m. China Standard...

2014-02-26 16:26:54

Study shows vaccine provides protection against EV71-associated hand, foot and mouth disease in infants and young children BEIJING, Feb. 26, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 ("EV71") vaccine have been published online in the February 27(th) issue of The New England Journal of Medicine ("NEJM"). The clinical results...

2014-02-25 20:21:36

DUBLIN, February 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jnwqq6/h1n1_vaccines) has announced the addition of the "H1N1 Vaccines - Global Strategic Business Report" [http://www.researchandmarkets.com/research/jnwqq6/h1n1_vaccines ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report analyzes the Global market for H1N1 Vaccines in US$ Million. The report provides...

2014-01-29 08:29:27

- Preclinical development completed for H7N9 vaccine candidates that addresses significant unmet medical need - BEIJING, Jan. 29, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to commence human clinical trials for its vaccine against Avian influenza A(H7N9) virus. The CTA was officially accepted...

2013-11-18 23:19:07

Reportbuyer.com just published a new market research report: China Human Vaccine Industry Report, 2012-2015. London (PRWEB) November 18, 2013 In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related